Short CommunicationKilling kinetics of minocycline, doxycycline and Tosufloxacin (cas 108138-46-1) against macrolide-resistant Mycoplasma pneumoniae

Add time:08/23/2019    Source:sciencedirect.com

Macrolide-resistant Mycoplasma pneumoniae (MRMP) has emerged and is increasing worldwide. In a 2011 outbreak of MRMP infections in Japan, symptoms failed to improve in many patients who initially received macrolides; the therapeutic agent was then changed to minocycline (MIN), doxycycline (DOX) or Tosufloxacin (cas 108138-46-1) (TFX). In this study, the bactericidal effects of these three agents against MRMP were evaluated. Time–kill kinetics against MRMP and macrolide-susceptible M. pneumoniae (MSMP) were determined for 5 days at concentrations corresponding to the respective minimum inhibitory concentration (MIC) and 2 × MIC, i.e. 1 µg/mL and 2 µg/mL for MIN, 0.5 µg/mL and 1 µg/mL for DOX, and 0.5 µg/mL and 1 µg/mL for TFX. The post-antibiotic effects (PAE) of these agents in culture against MRMP were also examined based on their pharmacokinetic parameters in children. Following exposure of MRMP and MSMP to up to twice the respective MICs of MIN, DOX and TFX, viable cells initially numbering 106 CFU/mL had decreased similarly to 103 CFU/mL after 4 days. Clarithromycin and azithromycin showed good bactericidal action against MSMP but not against MRMP. PAEs against MRMP appeared superior with MIN and DOX compared with TFX. In infection with M. pneumoniae having a generation time exceeding 6 h, a therapeutic agent must be selected in consideration of pharmacokinetic parameters, not MICs alone.

We also recommend Trading Suppliers and Manufacturers of Tosufloxacin (cas 108138-46-1). Pls Click Website Link as below: cas 108138-46-1 suppliers

Prev:Emergence of Haemophilus influenzae with low susceptibility to quinolones and persistence in Tosufloxacin (cas 108138-46-1) treatment
Next:Analysis of the spectroscopic characteristics on the binding interaction between Tosufloxacin (cas 108138-46-1) and bovine lactoferrin)